Innovation Drives Success in a Challenging Market
Danone has reinforced its commitment to specialised nutrition, including infant formula and Foods for Special Medical Purposes (FSMP), in China, where it achieved an 8.6% year-on-year sales increase to €1.8 billion in the first half of 2024. Despite challenges such as declining birth rates and intense market competition, Danone's success in China has been driven by a strong volume mix and a series of innovative product launches, such as Aptamil Essensis, designed to meet new national standards.
Strategic Innovation and Market Expansion
Danone’s focus on innovation is evident with the upcoming launch of Nuturis, an infant formula with large milk lipid droplets designed to mimic those in breast milk, set to debut in Hong Kong on September 1. The company is also expanding its tube feeding and FSMP offerings in China, aiming to build credibility with healthcare professionals and consumers through systematic and consistent product introductions. Danone’s strategy is not only maintaining but also enhancing its margins, ensuring sustainable growth in a competitive landscape.
Comments